To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

Inclusion Criteria: * At least 18 years of age * Hb \<11 g/dL (females) or Hb \<12 g/dL (males) at the screening visit * Serum ferritin \<100 ng/mL for subjects with underlying inflammatory disease (e.g., inflammatory bowel disease (IBD), chronic kidney disease (CKD) or chronic heart failure (CHF), as determined by high sensitive C-reactive protein \[hsCRP\] levels above the normal range) otherwise ≤14 ng/mL in subjects with no apparent underlying inflammatory disease (as determined by hsCRP levels within normal range) at the screening visit * Transferrin Saturation (TSAT) \<16% (any subject) at the screening visit * Microcytic, hypochromic anaemia defined as: a) Mean corpuscular Hb concentration (MCHC) \<32%; b) Mean corpuscular volume (MCV) \< 80 fL; c)Mean corpuscular Hb (MCH) \<27 pg * Subjects with the ability to understand the requirements of the study and abide by the study restrictions, and who agree to return for the required assessments * Before any study-specific procedure is conducted, the appropriate written informed consent must be obtained Exclusion Criteria: * Subject has known hypersensitivity to any of the products to be administered during dosing * Any history of iron storage diseases such as haemochromatosis * Any history or clinical findings of iron utilisation disorders such as sideroachrestic anaemia * Known haemoglobinopathy (e.g. thalassaemia) * Any history or clinical findings of anaemia associated with: a) Haematuria b) Vitamin B12 or folic acid deficiency that requires treatment (subjects can be included after deficiency is corrected) * Any allergic predispositions, i.e. any history of asthma or atopic allergy. This includes drug allergies. * Planned surgery with anticipated blood loss (defined as Hb drop \>2 g/dL) in the 3 months post randomisation * Subject has known malignancy (with or without current treatment), except basal cell or squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia * Haemodialysis (current or planned within the next 3 months) * History of IV iron therapy, erythropoiesis stimulating agent (ESA) therapy and/or blood transfusion in previous 4 weeks prior to screening, and oral iron or oral iron-containing products including Chinese herbal medicines (\>75mg iron/day) in the 7 days prior to screening * Body weight \<35 kg * Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) above 3 times the upper limit of the normal range * Known human immunodeficiency virus infection, acquired immunodeficiency syndrome, tuberculosis * Known active hepatitis B or C or other active infection (acute or chronic) * Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(ies), or subject is receiving other investigational agent(s) * Subject is pregnant or is breast feeding * Female subject of childbearing potential not using adequate contraceptive methods during the study and for up to 1 month after the last dose of the study medication. Adequate contraceptive methods are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilised at least 6 months prior to the study or post-menopausal, defined as amenorrhoea for at least 12 months * Male subjects planning to father a child within 7 days from the last study drug administration. * Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures and/or other reason(s) that render subject not appropriate for study participation in the opinion of the treating physician